Background and Objectives: To our knowledge, this is the first study that investigated the prognostic value of radiomics features extracted from not only staging 18F-fluorodeoxyglucose positron emission tomography (FDG PET/CT) images, but also post-induction chemotherapy (ICT) PET/CT images. This study aimed to construct a training model based on radiomics features obtained from PET/CT in a cohort of patients with locally advanced head and neck squamous cell carcinoma treated with ICT, to predict locoregional recurrence, development of distant metastases, and the overall survival, and to extract the most significant radiomics features, which were included in the final model. Materials and Methods: This retrospective study analyzed data of 55 patients. All patients underwent PET/CT at the initial staging and after ICT. Along the classical set of 13 parameters, the original 52 parameters were extracted from each PET/CT study and an additional 52 parameters were generated as a difference between radiomics parameters before and after the ICT. Five machine learning algorithms were tested. Results: The Random Forest algorithm demonstrated the best performance (R2 0.963–0.998) in the majority of datasets. The strongest correlation in the classical dataset was between the time to disease progression and time to death (r = 0.89). Another strong correlation (r ≥ 0.8) was between higher-order texture indices GLRLM_GLNU, GLRLM_SZLGE, and GLRLM_ZLNU and standard PET parameters MTV, TLG, and SUVmax. Patients with a higher numerical expression of GLCM_ContrastVariance, extracted from the delta dataset, had a longer survival and longer time until progression (p = 0.001). Good correlations were observed between Discretized_SUVstd or Discretized_SUVSkewness and time until progression (p = 0.007). Conclusions: Radiomics features extracted from the delta dataset produced the most robust data. Most of the parameters had a positive impact on the prediction of the overall survival and the time until progression. The strongest single parameter was GLCM_ContrastVariance. Discretized_SUVstd or Discretized_SUVSkewness demonstrated a strong correlation with the time until progression.
Introduction: Radiotherapy is a vital therapeutic option in the treatment of breast cancer nowadays. However, a major obstacle to the full effectiveness of radiation therapy is still the radioresistance of cancer cells. Various studies have proven sulforaphane's (SFN) beneficial effects against cancer and its possible utilization as a radiosensitizer in radiotherapy. This study aimed to investigate whether SFN has a radiosensitizing effect on breast cancer cells.Material and methods: The anticancer efficiency of SFN and radiosensitizing effect in MCF-7 and MDA-MB-231 cell lines were assessed by the MTT assay. Using a flow cytometric assay, the apoptosis level and changes in the cell cycle were measured. RT-qPCR and Western blot analysis were used to determine BCL-2 and BCL-XL genes expresion and proteins level.Results: According to our results, SFN reduced the viability of cells, and combining SFN with radiation therapy (IR) caused much greater anticancer effects on cells. SFN+IR was shown to enhance the number of cells in the G2/M phase and the percentage of cells going through apoptosis. SFN reduced the expression of apoptosis-relative genes BCL-2 and BCL-XL. Consistent with this data, Western blot analysis revealed that BCL-2 and BCL-XL protein levels were decreased in tested cells. As a result of the combination treatment, the downregulation of the BCL-2 protein was observed only in MDA-MB-231 cells.Conclusions: These results indicate that SFN acts as a radiosensitizer by enhancing apoptotic cell death and reducing anti-apoptotic genes in breast cancer cells.
Background and Objectives: Early-stage glottic cancer requires highly precise radiotherapy due to laryngeal motion and the proximity of critical structures. Magnetic resonance-guided radiotherapy (MRgRT) enables real-time visualization and motion management, potentially improving dose conformity while reducing treatment margins. This pilot comparative planning study compared the dosimetric characteristics of MR-guided intensity-modulated radiotherapy (IMRT) delivered on the Unity MR-linac with volumetric modulated arc therapy (VMAT) plans generated for the TrueBeam STx and Halcyon systems. Materials and Methods: Ten patients with T1–T2N0 glottic squamous cell carcinoma were included. For each patient, treatment plans prescribing 42.5 Gy in five fractions were generated using all three systems. Planning target volume (PTV) coverage, conformity index (CI), homogeneity index (HI), organ-at-risk (OAR) doses, monitor units, and beam-on times were compared using Friedman and post hoc Wilcoxon signed-rank tests. Results: Unity achieved superior dose conformity (CI 0.97 ± 0.01 vs. 0.78 ± 0.15 for TrueBeam STx and 0.58 ± 0.19 for Halcyon; p < 0.001) and the highest mean dose, while PTV coverage (D95% and D98%) was comparable to TrueBeam STx and higher than Halcyon. Reduced treatment margins resulted in significantly smaller PTV volumes (11.09 ± 3.87 cm3 vs. 17.43 ± 4.75 cm3; p = 0.0001). Halcyon demonstrated the most homogeneous dose distribution (HI 7.88 ± 3.14), whereas TrueBeam STx showed intermediate homogeneity (HI 12.81 ± 3.90). Most OAR dose metrics were comparable among techniques, although selected laryngeal structures and the esophagus differed significantly. Beam-on time was longest for Unity. Conclusions: MR-guided IMRT provided superior dose conformity while maintaining target coverage comparable to TrueBeam STx with clinically acceptable OAR sparing. Prospective clinical studies are required to determine whether these dosimetric advantages translate into improved patient outcomes.